and at least one *Perna canaliculus* component, both in a non-injectable form for administration.

15. (Twice Amended) A kit comprising a dimethylglycine formulation in a non-injectable form and a *Perna canaliculus* formulation in a non-injectable form, wherein the *Perna canaliculus* formulation comprises at least one *Perna canaliculus* component.

Add the following new claims:

- **20.** The composition of claim 12, wherein the composition is in a form suitable for oral administration.
- 21. The kit of claim 15, wherein both the dimethylglycine formulation and the *Perna canaliculus* formulation are in a form suitable for oral administration.
- 22. A method for treating lupus erythmatosus, which comprises administering to a patient in need of such treatment an effective amount of a composition according to claim 12.
 - 23. The method of claim 22, wherein the composition is administered orally.
- 24. The method of claim 22, wherein the amount of dimethylglycine component administered is from 1 to 500 mg/kg/day and the amount of at least one *Perna canaliculus* component administered is from 1 to 500 mg/kg/day.

- The method of claim 22, wherein the amount of dimethylglycine component administered is from 10 to 100 mg/kg/day and the amount of at least one Perna canaliculus component administered is from 10 to 100 mg/kg/day.
- 26. A method for treating lupus erythmatosus, which comprises administering to a patient in need of such\treatment effective amounts of a dimethylglycine formulation and a Perna canaliculus formulation from a kit according to claim 15.
- 27. The method of daim 26, wherein the dimethylglycine formulation and the Perna canaliculus formulation are administered orally.
- The method of claim 26, wherein the amount of dimethylglycine administered 28. is from 1 to 500 mg/kg/day and the amount of at least one Perna canaliculus component administered is from 1 to 500 mg/kg/day.
- 29. The method of dlaim 26, wherein the amount of dimethylglycine administered is from 10 to 100 mg/kg/day and the amount of at least one *Perna canaliculus* component administered is from 10 to 100 mg/kg/day
- A method for modulating the immune response of a patient to decrease the **30.** serum levels of il-6, decrease the serum levels of il-10, in αrease the serum levels of TNF-α and decrease the concentration of CD8⁺ lymphocytes in the blood which comprises administering to a patient in need of such treatment an effective amount of a composition according to claim 12.

3

- 31. A method for modulating the immune response of a patient to decrease the serum levels of il-6, decrease the serum levels of il-10, increase the serum levels of TNF- α and decrease the concentration of CD8⁺ lymphocytes in the blood which comprises administering to a patient in need of such treatment effective amounts of a dimethylglycine formulation and a *Perna canaliculus* formulation from a kit according to claim 15.
- 32. The method of claim 30, wherein the amount of dimethylglycine component administered is from 1 to 500 mg/kg/day and the amount of at least one *Perna canaliculus* component administered is from 1 to 500 mg/kg/day.
- 33. The method of claim 30, wherein the amount of dimethylglycine component administered is from 10 to 100 mg/kg/day and the amount of at least one *Perna canaliculus* component administered is from 10 to 100 mg/kg/day.
- 34. The method of claim 31, wherein the amount of dimethylglycine administered is from 1 to 500 mg/kg/day and the amount of at least one *Perna canaliculus* component administered is from 1 to 500 mg/kg/day.
- 35. The method of claim 31, wherein the amount of dimethylglycine administered is from 10 to 100 mg/kg/day and the amount of at least one *Perna canaliculus* component administered is from 10 to 100 mg/kg/day.
 - 36. The method of claim 30, wherein the composition is administered orally.

- 37. The method of claim 31, wherein the dimethylglycine formulation and the Perna canaliculus formulation are administered orally.
- **38.** The composition of claim 12, wherein the *Perna canaliculus* component is provided as unrefined whole *Perna canaliculus* mussel.
- **39.** The kit of claim 15, wherein the *Perna canaliculus* formulation is provided as unrefined whole *Perna canaliculus* mussel.
- 40. The composition of claim 12, wherein the *Perna canaliculus* component is provided as an extract of at least one therapeutically active component of *Perna canaliculus* mussel.
- 41. The kit of claim 15, wherein the *Perna canaliculus* formulation is provided as an extract of at least one therapeutically active component of *Perna canaliculus* mussel. —.